{"id":"W2122553809","doi":"10.1016/s0140-6736(08)61758-4","title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Internal medicine; Regimen; Hazard ratio; Population; Oncology; Chemotherapy; Performance status; Cancer; Epidermal growth factor receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06467038308692118,"score_gpt":0.372727022308989,"score_spread":0.3080566392220678,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}